BEL536 - Belenos Biosciences
...Second Asset BEL536, a First-in-class Long-acting Bispecific Targeting OX40L and IL-13... (Businesswire) - Nov 10, 2025 - "CTN filed in Australia with target of initiating Phase 1 study in 1Q2026." 
New P1 trial • Inflammation
https://www.businesswire.com/news/home/20251110761345/en/Belenos-Pipeline-Updates-First-Clinical-Data-from-Lead-Asset-BEL512-a-Long-lasting-Bispecific-Targeting-TSLP-and-IL-13-Second-Asset-BEL536-a-First-in-class-Long-acting-Bispecific-Targeting-OX40L-and-IL-13-Phase-1-to-Start-1Q2026
 
Nov 10, 2025